Moreover, the differential roles of specific defensins (e.g., tumor-suppressive DEFA5 vs. tumor-promoting DEFA6) highlight the complexity of AMP regulation in CRC and suggest that targeted modulation of AMP pathways could represent a novel therapeutic strategy for CRC [35]. The gene discussed is DEFA6; the disease is colorectal carcinoma.